Source - RNS
RNS Number : 0521K
The MedicX Fund Limited
16 September 2016



For immediate release

16 September 2016


MedicX Fund Limited

("MedicX Fund", "the Fund" or "the Company")



£20 million revolving loan facility


MedicX Fund Limited (LSE: MXF), the specialist primary care infrastructure investor in modern purpose-built primary healthcare properties in the United Kingdom and Republic of Ireland, is pleased to announce that it has completed the amendment and restatement of its previous £25 million revolving credit facility.

On 15 September 2016, the facility term was extended for a new three year term ending in September 2019. In addition, the amendment also provides for an option, with lender consent, that the immediately committed £20 million revolving credit facility may be extended by a further £10 million to £30 million or additional lenders be added with a view to increasing the facility on existing terms.

Interest is payable on amounts drawn under the amended facility at a rate equal to LIBOR plus a lending margin of 2.00 per cent. per annum. A non-utilisation fee of between 1.10% and 0.75% will be payable on the reduced, £20 million immediately available commitment depending on the level of utilisation.   

The Fund has £337 million of other debt facilities with a weighted average fixed cost of 4.45% including undrawn amounts, with an average remaining term of just over 14 years. 



- End -



For further information please contact:


MedicX Fund                                                                  +44 (0) 1481 723 450

David Staples, Chairman


Octopus Healthcare Group                                               +44 (0) 20 3142 4820

Mike Adams, Chief Executive Officer


Canaccord Genuity                                                          +44 (0) 20 7523 8000

Andrew Zychowski/Helen Goldsmith        


Buchanan                                                                      +44 (0) 20 7466 5000

Charles Ryland/Vicky Hayns


Information on MedicX Fund Limited


MedicX Fund Limited (the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom and Ireland, listed on the London Stock Exchange, with a portfolio comprising 152 properties.

The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is part of the Octopus Healthcare group. Octopus Healthcare invests in and develops properties as well as creating partnerships to deliver innovative healthcare buildings to improve the health, wealth and wellbeing of the UK. It currently manages over £1 billion of healthcare investments across a number of platforms, with a focus on four core areas: GP surgeries, care homes, retirement housing and private hospitals. Octopus Healthcare is part of the Octopus group, a fast-growing UK fund management business with leading positions in several specialist sectors including healthcare property, energy, property finance and smaller company investing. Octopus manages £5.5 billion of funds for more than 50,000 retail and institutional investors.

Octopus Healthcare Adviser Ltd is authorised and regulated by the Financial Conduct Authority.

The Company's website address is Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website), nor the contents of any website accessible from hyperlinks within this announcement, are incorporated into, or forms part of, this announcement.


This information is provided by RNS
The company news service from the London Stock Exchange